Kelly M. Credille

TL;DR: A small cyclic peptide, LY2510924, which is a potent and selective CXCR4 antagonist currently in phase II clinical studies for cancer, showed dose-dependent inhibition of tumor growth in human xenograft models developed with non–Hodgkin lymphoma, renal cell carcinoma, lung, and colon cancer cells that express functional CX CR4.

TL;DR: The findings indicate that the mechanism of action of LY2875358 is different from that of the one-armed MET antibody, which may provide a promising therapeutic strategy for patients whose tumors are driven by both HGF-dependent and H GF-independent MET activation.

TL;DR: This review examines the development of the rat mammary gland and the influence of sex hormones on the morphology of the adult male and female rat Mammary gland to predict potential xenobiotic-induced perturbations in the systemic hormonal milieu.

TL;DR: Results support clinical evaluation of LY2801653 in NSCLCs and suggest that differences in the MET activation of tumors may be predictive of response, as well as supporting in vitro findings confirmed in the H441 orthotopic model.

TL;DR: Fabp3 was the most useful individual biomarker based on concordance, sensitivity, positive and negative predictive values, and false negative rate and the combination of Fabp3 and aspartate aminotransferase (AST) had greater diagnostic value than the conventional combination of creatine kinase-MM isoenzyme (CK) and AST.